Meeqaat H. Altrufi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Meeqaat H. Altrufi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Haider Falih Shamikh Al-Saedi
Department of Pharmacology and Toxicology, College of Pharmacy, University of Al-Ameed, Karbala 56001, Iraq
2 shared publications - Mohammed Ibrahim Rasool
Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala 56001, Iraq
2 shared publications - Samer Ali Hasan
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Kufa, Najaf 54001, Iraq
2 shared publications - Waleed Khaled Albahadly
DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, COLLEGE OF PHARMACY, UNIVERSITY OF KARBALA, KARBALA, IRAQ
2 shared publications - Jamal Ali Ashoor
Department of Pharmaceutics, College of Pharmacy, University of Karbala, Karbala 56001, Iraq
1 shared publication - Mohammed Abdulaali Sahib
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Kerbala, Karbala 56001, Iraq
1 shared publication
Latest Publications
- Open Access
Nicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NAD+ Homeostasis and Nrf2/NQO1-Dependent Antioxidant Signaling
Background: Cisplatin is a widely used chemotherapeutic agent whose clinical application is often limited by severe hepatorenal toxicity associated with oxidative stress and cellular injury. Nicotinamide riboside (NR), a natural precursor of nicotinamide adenine dinucleotide (NAD+), has emerged as a promising cytoprotective compound with antioxidant and metabolic regulatory properties. This study investigated the protective effects of NR against cisplatin-induced hepatorenal toxicity and explored its potential mechanisms of action. Methods: Thirty-six adult male Wistar rats were randomly assigned to four groups (n = 6): control, cisplatin (7 mg/kg, i.p.), nicotinamide riboside (50 mg/kg/day, orally), and cisplatin plus NR. Renal and hepatic function biomarkers, lipid profile parameters, oxidative stress markers, and antioxidant status were evaluated. Relative mRNA expression of Nrf2 and NQO1 was determined using RT-qPCR. Histopathological examinations of liver and kidney tissues were also performed. Results: Cisplatin administration induced marked hepatorenal injury, evidenced by significant elevations in serum KIM-1 (395.27 vs. 116.04 ng/mL), urea (71.16 vs. 21.33 mg/dL), creatinine (3.49 vs. 0.26 mg/dL), AST (325.83 vs. 95.16 U/L), and ALT (102.83 vs. 45.50 U/L), accompanied by dyslipidemia, oxidative stress, and severe histopathological alterations. NR treatment significantly attenuated these changes, reducing KIM-1, urea, creatinine, AST, and ALT by 55.5%, 47.8%, 48.1%, 55.4%, and 33.5%, respectively, compared with the cisplatin group. NR also improved antioxidant status by increasing GSH and SOD levels while reducing MDA and NO concentrations. Hepatic NAD+ levels and the NAD+/NADH ratio were significantly decreased by cisplatin and significantly restored by NR treatment. In addition, NR significantly upregulated the relative mRNA expression of Nrf2 and NQO1 and markedly preserved hepatic and renal histological architecture. Pharmacological inhibition of Nrf2 with ML385 significantly attenuated these protective effects of NR across biochemical, lipid, and oxidative stress parameters, confirming that they are, at least in part, Nrf2-dependent. Conclusions: Nicotinamide riboside exerts protective effects against cisplatin-induced hepatorenal toxicity that are mechanistically linked to activation of the Nrf2/NQO1 antioxidant pathway and restoration of hepatic NAD+ homeostasis. This finding supports the potential of NR as an adjunctive strategy for mitigating cisplatin-associated hepatorenal injury and warrants further preclinical and clinical investigation.
Open AccessNicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NAD+ Homeostasis and Nrf2/NQO1-Dependent Antioxidant Signaling
Background: Cisplatin is a widely used chemotherapeutic agent whose clinical application is often limited by severe hepatorenal toxicity associated with oxidative stress and cellular injury. Nicotinamide riboside (NR), a natural precursor of nicotinamide adenine dinucleotide (NAD+), has emerged as a promising cytoprotective compound with antioxidant and metabolic regulatory properties. This study investigated the protective effects of NR against cisplatin-induced hepatorenal toxicity and explored its potential mechanisms of action. Methods: Thirty-six adult male Wistar rats were randomly assigned to four groups (n = 6): control, cisplatin (7 mg/kg, i.p.), nicotinamide riboside (50 mg/kg/day, orally), and cisplatin plus NR. Renal and hepatic function biomarkers, lipid profile parameters, oxidative stress markers, and antioxidant status were evaluated. Relative mRNA expression of Nrf2 and NQO1 was determined using RT-qPCR. Histopathological examinations of liver and kidney tissues were also performed. Results: Cisplatin administration induced marked hepatorenal injury, evidenced by significant elevations in serum KIM-1 (395.27 vs. 116.04 ng/mL), urea (71.16 vs. 21.33 mg/dL), creatinine (3.49 vs. 0.26 mg/dL), AST (325.83 vs. 95.16 U/L), and ALT (102.83 vs. 45.50 U/L), accompanied by dyslipidemia, oxidative stress, and severe histopathological alterations. NR treatment significantly attenuated these changes, reducing KIM-1, urea, creatinine, AST, and ALT by 55.5%, 47.8%, 48.1%, 55.4%, and 33.5%, respectively, compared with the cisplatin group. NR also improved antioxidant status by increasing GSH and SOD levels while reducing MDA and NO concentrations. Hepatic NAD+ levels and the NAD+/NADH ratio were significantly decreased by cisplatin and significantly restored by NR treatment. In addition, NR significantly upregulated the relative mRNA expression of Nrf2 and NQO1 and markedly preserved hepatic and renal histological architecture. Pharmacological inhibition of Nrf2 with ML385 significantly attenuated these protective effects of NR across biochemical, lipid, and oxidative stress parameters, confirming that they are, at least in part, Nrf2-dependent. Conclusions: Nicotinamide riboside exerts protective effects against cisplatin-induced hepatorenal toxicity that are mechanistically linked to activation of the Nrf2/NQO1 antioxidant pathway and restoration of hepatic NAD+ homeostasis. This finding supports the potential of NR as an adjunctive strategy for mitigating cisplatin-associated hepatorenal injury and warrants further preclinical and clinical investigation.
- Open Access
Topical Astaxanthin Attenuates Imiquimod-Induced Psoriasiform Dermatitis by Downregulating Psoriasis-Associated Keratin Gene Expression (Krt16, Krt17, Krt6a) and Inhibiting the JAK-STAT Signaling Pathway
Psoriasis is a chronic immune-mediated inflammatory skin disorder characterized by excessive keratinocyte proliferation, oxidative stress, and dysregulated cytokine signaling. Although topical corticosteroids remain the first-line therapy, their long-term use is often limited by adverse effects, highlighting the need for safer non-steroidal therapeutic alternatives. This study investigated the therapeutic efficacy and underlying mechanisms of a topical astaxanthin (AST) formulation in an imiquimod (IMQ)-induced mouse model of psoriasiform dermatitis. Following IMQ induction, mice were randomly assigned to vehicle, clobetasol, or AST treatment groups (0.5–1.5%) for 14 days. Disease progression was evaluated through biochemical analysis of oxidative stress biomarkers, including NADPH oxidase (NOX), malondialdehyde (MDA), nitric oxide (NO), and superoxide dismutase (SOD), as well as ELISA-based quantification of inflammatory cytokines (TNF-α, IL-6, IL-17, and IL-23). Histopathological changes were assessed using hematoxylin and eosin staining, while molecular alterations were examined by RT-qPCR analysis of psoriasis-associated keratin genes (Krt16, Krt17, and Krt6a) and evaluation of JAK–STAT signaling activity. AST treatment significantly suppressed the IL-23/IL-17 inflammatory axis, reduced NOX activity and lipid peroxidation, restored endogenous antioxidant defenses, and inhibited JAK–STAT signaling. These biochemical and molecular effects were accompanied by marked downregulation of keratin gene expression and substantial histological improvement, including normalization of epidermal thickness, reduced parakeratosis, and decreased inflammatory infiltration. Notably, high-dose AST demonstrated therapeutic efficacy comparable to, and in some parameters exceeding, that of clobetasol. Collectively, these findings indicate that topical astaxanthin exerts coordinated antioxidant, anti-inflammatory, and anti-proliferative effects, supporting its potential as a promising multi-target non-steroidal therapeutic candidate for psoriasis management.
Open AccessTopical Astaxanthin Attenuates Imiquimod-Induced Psoriasiform Dermatitis by Downregulating Psoriasis-Associated Keratin Gene Expression (Krt16, Krt17, Krt6a) and Inhibiting the JAK-STAT Signaling Pathway
Psoriasis is a chronic immune-mediated inflammatory skin disorder characterized by excessive keratinocyte proliferation, oxidative stress, and dysregulated cytokine signaling. Although topical corticosteroids remain the first-line therapy, their long-term use is often limited by adverse effects, highlighting the need for safer non-steroidal therapeutic alternatives. This study investigated the therapeutic efficacy and underlying mechanisms of a topical astaxanthin (AST) formulation in an imiquimod (IMQ)-induced mouse model of psoriasiform dermatitis. Following IMQ induction, mice were randomly assigned to vehicle, clobetasol, or AST treatment groups (0.5–1.5%) for 14 days. Disease progression was evaluated through biochemical analysis of oxidative stress biomarkers, including NADPH oxidase (NOX), malondialdehyde (MDA), nitric oxide (NO), and superoxide dismutase (SOD), as well as ELISA-based quantification of inflammatory cytokines (TNF-α, IL-6, IL-17, and IL-23). Histopathological changes were assessed using hematoxylin and eosin staining, while molecular alterations were examined by RT-qPCR analysis of psoriasis-associated keratin genes (Krt16, Krt17, and Krt6a) and evaluation of JAK–STAT signaling activity. AST treatment significantly suppressed the IL-23/IL-17 inflammatory axis, reduced NOX activity and lipid peroxidation, restored endogenous antioxidant defenses, and inhibited JAK–STAT signaling. These biochemical and molecular effects were accompanied by marked downregulation of keratin gene expression and substantial histological improvement, including normalization of epidermal thickness, reduced parakeratosis, and decreased inflammatory infiltration. Notably, high-dose AST demonstrated therapeutic efficacy comparable to, and in some parameters exceeding, that of clobetasol. Collectively, these findings indicate that topical astaxanthin exerts coordinated antioxidant, anti-inflammatory, and anti-proliferative effects, supporting its potential as a promising multi-target non-steroidal therapeutic candidate for psoriasis management.
- Open Access
- 31 December 2025
- Published by College of Pharmacy, University of Kerbala in Karbala Journal of Pharmaceutical Sciences
- Vol. 16 (27) , 25-43
Synthesis, in silico Biological and ADMET Predictions, and Molecular Docking of Isatin Schiff Base Derivatives as Promising Antituberculosis Agents
Tuberculosis (TB), caused by Mycobacterium tuberculosis, continues to be a global health challenge, particularly with the rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. In this study, five isatin Schiff base derivatives were designed, synthesized, and evaluated using in silico approaches to identify potential antitubercular agents. The ADMET profiles of isatin Schiff base derivatives were studied via pkCSM, admetSAR, and SwissADME servers. Biological activity predictions were conducted using the PASS online tool, with significant activity considered at Pa > 0.7. Molecular docking studies were performed using MOE software targeting the InhA enzyme (PDB ID: 4TZK), a key protein in the fatty acid synthesis pathway of Mycobacterium tuberculosis. The docking results revealed that all five ligands exhibited favorable binding affinities and strong interactions with the enzyme’s active site. Additionally, the ADMET profiles suggested good drug-likeness and acceptable pharmacokinetic behavior. These findings suggest that the synthesized isatin Schiff base derivatives (A1–A5) are promising candidates for further development as antitubercular agents. Conclusion: This study demonstrated that the five isatin Schiff base derivatives (A1–A5) show strong potential as antitubercular agents. Molecular docking revealed promising interactions with the InhA enzyme, especially for ligand A5. ADMET studies analyses further supported their drug-likeness and biological activity. These findings warrant further experimental validation and optimization.
- 31 December 2025
- Published by College of Pharmacy, University of Kerbala in Karbala Journal of Pharmaceutical Sciences
- Vol. 16 (27) , 25-43
Open AccessSynthesis, in silico Biological and ADMET Predictions, and Molecular Docking of Isatin Schiff Base Derivatives as Promising Antituberculosis Agents
Tuberculosis (TB), caused by Mycobacterium tuberculosis, continues to be a global health challenge, particularly with the rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. In this study, five isatin Schiff base derivatives were designed, synthesized, and evaluated using in silico approaches to identify potential antitubercular agents. The ADMET profiles of isatin Schiff base derivatives were studied via pkCSM, admetSAR, and SwissADME servers. Biological activity predictions were conducted using the PASS online tool, with significant activity considered at Pa > 0.7. Molecular docking studies were performed using MOE software targeting the InhA enzyme (PDB ID: 4TZK), a key protein in the fatty acid synthesis pathway of Mycobacterium tuberculosis. The docking results revealed that all five ligands exhibited favorable binding affinities and strong interactions with the enzyme’s active site. Additionally, the ADMET profiles suggested good drug-likeness and acceptable pharmacokinetic behavior. These findings suggest that the synthesized isatin Schiff base derivatives (A1–A5) are promising candidates for further development as antitubercular agents. Conclusion: This study demonstrated that the five isatin Schiff base derivatives (A1–A5) show strong potential as antitubercular agents. Molecular docking revealed promising interactions with the InhA enzyme, especially for ligand A5. ADMET studies analyses further supported their drug-likeness and biological activity. These findings warrant further experimental validation and optimization.